| Budget Amount *help |
¥40,170,000 (Direct Cost: ¥30,900,000、Indirect Cost: ¥9,270,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2017: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2016: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
Fiscal Year 2015: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2014: ¥12,480,000 (Direct Cost: ¥9,600,000、Indirect Cost: ¥2,880,000)
|
|---|
| Outline of Final Research Achievements |
In this 5-y study, we discovered 19 new compounds of microbial origin with lipid metabolism regulatory activity. Regarding the highly SOAT2-selective inhibitor, pyripyropene A (PPPA), certain semisynthetic pyripyropene derivatives (PRDs) with more potent and more selective inhibitory activity against SOAT2 showed more potent in vivo atheroprotective activity in mouse models than PPPA and blocked fatty liver progression in Wolman disease mouse model. Thus, PRDs with SOAT2-selective inhibition will be the first-in-class drug for the treatment/prevention of haypercholesterolemia, atherosclerosis, fatty liver diseases.
|
